全文获取类型
收费全文 | 69490篇 |
免费 | 3772篇 |
国内免费 | 301篇 |
专业分类
耳鼻咽喉 | 1444篇 |
儿科学 | 2303篇 |
妇产科学 | 1616篇 |
基础医学 | 9038篇 |
口腔科学 | 2426篇 |
临床医学 | 4744篇 |
内科学 | 16829篇 |
皮肤病学 | 2380篇 |
神经病学 | 5674篇 |
特种医学 | 1498篇 |
外国民族医学 | 1篇 |
外科学 | 8597篇 |
综合类 | 482篇 |
一般理论 | 21篇 |
预防医学 | 6844篇 |
眼科学 | 1293篇 |
药学 | 4888篇 |
中国医学 | 452篇 |
肿瘤学 | 3033篇 |
出版年
2023年 | 470篇 |
2022年 | 398篇 |
2021年 | 2364篇 |
2020年 | 1288篇 |
2019年 | 2366篇 |
2018年 | 2775篇 |
2017年 | 1655篇 |
2016年 | 1601篇 |
2015年 | 1781篇 |
2014年 | 2676篇 |
2013年 | 3704篇 |
2012年 | 5205篇 |
2011年 | 5533篇 |
2010年 | 3106篇 |
2009年 | 2612篇 |
2008年 | 3916篇 |
2007年 | 4070篇 |
2006年 | 3768篇 |
2005年 | 3796篇 |
2004年 | 3427篇 |
2003年 | 3133篇 |
2002年 | 2829篇 |
2001年 | 1590篇 |
2000年 | 1737篇 |
1999年 | 1408篇 |
1998年 | 390篇 |
1997年 | 336篇 |
1996年 | 260篇 |
1995年 | 291篇 |
1994年 | 242篇 |
1993年 | 183篇 |
1992年 | 534篇 |
1991年 | 434篇 |
1990年 | 417篇 |
1989年 | 313篇 |
1988年 | 316篇 |
1987年 | 283篇 |
1986年 | 251篇 |
1985年 | 239篇 |
1984年 | 148篇 |
1983年 | 148篇 |
1982年 | 115篇 |
1981年 | 125篇 |
1980年 | 94篇 |
1979年 | 143篇 |
1978年 | 109篇 |
1974年 | 109篇 |
1971年 | 88篇 |
1969年 | 87篇 |
1968年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
1.
Tiago Ribeiro Leal Larissa Chaves Morais de Lima rick Tssio Barbosa Neves Maria Jacinta Arêa Leo Lopes Araújo Arruda Matheus Frana Perazzo Saul Martins Paiva Júnia Maria Serra-Negra Fernanda de Morais Ferreira Ana Flvia Granville-Garcia 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2022,32(1):22-30
2.
3.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
4.
Traboulsi-Garet Bassel Jorba-García Adrià Camps-Font Octavi Alves Fabio Abreu Figueiredo Rui Valmaseda-Castellón Eduard 《Clinical oral investigations》2022,26(3):2371-2382
Clinical Oral Investigations - To determine the usefulness of Serum C-terminal telopeptide cross-link of type 1 collagen (sCTX) as a preoperative marker for predicting the risk of developing... 相似文献
5.
Juan Carlos Casado-Morente Elena Mora Rivas Carlos O’Connor Reina Soledad Angulo Serrano Estefanía Díaz-Fresno Isabel Sandoval-Menéndez Antonio Becerra M. Jesús Lucio Faustino Núñez-Batalla 《Acta otorrinolaringologica espanola》2021,72(1):21-26
ObjectiveThe aim of this study was to create and validate an abbreviated version of the Spanish Transsexual Voice Questionnaire for Male-to-Female Transsexuals (SvTVQMtF).SettingThe study was conducted by two referral hospitals for voice feminization surgery and by a university department of psychology and speech therapy, all in Spain.Subjects and methodsWe prospectively studied 51 male-to-female transsexuals who underwent voice feminization surgery between January 2017 and December 2018. The SvTVQMtF was completed before and after surgery, and the 10 items with the greatest variation were selected by clinical consensus of an expert panel to develop the short version of the SvTVQMtF (SvTVQMtF-10). The correlation between the total score and the score for each item on the SvTVQMtF and the SvTVQMtF-10 was studied. The internal consistency of the SvTVQMtF-10 was analysed.ResultsGood correlation (Pearson coefficient above .90) was found between the two questionnaires. A significant correlation was found between the total SvTVQMtF-10 score and the score for each item. A significant negative correlation was found between the SvTVQMtF and fundamental frequency after voice feminization surgery. Cronbach's α was .79.ConclusionThe SvTVQMtF-10 is a valid short version of the SvTVQMtF and can be used to quantify voice-related quality of life in MtF transsexuals. 相似文献
6.
7.
Francisco José Álvarez García María José Cilleruelo Ortega Javier Álvarez Aldeán María Garcés-Sánchez Nuria García Sánchez Elisa Garrote Llanos Ángel Hernández Merino Antonio Iofrío de Arce Abián Montesdeoca Melián María Luisa Navarro Gómez Jesús Ruiz-Contreras 《Anales de pediatría (Barcelona, Spain : 2003)》2021,94(1):53.e1-53.e10
The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence.The 2 + 1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2 + 1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks.Rotavirus vaccine should be systematic for all infants.Meningococcal B vaccine, with a 2 + 1 schedule, should be included in routine calendar.In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups.Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine.Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders. 相似文献
8.
9.
Natalia P. Schütz Paola Ochoa Patricio Duarte Guillermina Remaggi Sebastián Yantorno Ariel Corzo Soledad Zabaljauregui Claudia Shanley Sergio Lopresti Sergio Orlando Verónica Verri Luis Quiroga Carlos A. García Vanesa Fernández Dorotea Fantl 《Hematological oncology》2020,38(3):363-371
Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients. Most common options are CyBorD (cyclophosphamide, bortezomib and dexamethasone) and VTD (bortezomib, thalidomide and dexamethasone). Main goal of our retrospective, multicentric study was to compare very good partial response rate (VGPR) or better after induction treatment in a real-world setting in Argentina. Secondary objectives included comparison of complete response (CR) post-induction and after bone marrow transplantation, grade 3-4 adverse events (AEs), progression-free survival (PFS) and overall survival (OS). Three hundred twenty-two patients were included (median age at diagnosis: 57 years; 52% male; 28% had ISS3; 14% with high-risk cytogenetics; median follow up: 34 months). CyBorD was indicated in 74% and 26% received VTD. In VTD arm, 72.62% of patients achieved at least VGPR vs 53.36% receiving CyBorD (odds ratio, OR: 1.96 [95% confidence interval, CI: 1.08-3.57; P = .026] after adjusting by age, ISS [International Staging System], lactate dehydrogenase levels (LDH) and cytogenetic risk. Difference in VGPR was 19.26% (95% CI: 15-24). CR rate were 35.92% (VTD) vs 22.55% (CyBorD) (adjusted OR: 2.13 [95% CI: 1.12-4.05]). Difference in CR was 13.37% (95% CI: 9.6-17.53). Adverse events (AEs) were more common with VTD (69.05% vs 55.46% for CyBorD; P = .030), especially grade 3-4 neuropathy (P = .005) and thrombosis (P = .001). Thromboprophylaxis was inadequate in 20.24% of patients. Hematological AEs were more common with CyBorD, especially thrombocytopenia (P = .017). PFS and OS at 24 months were not different between treatments. In this real-world setting, VTD was associated with better CR and VGPR than CyBorD. Nevertheless, CyBorD continues to be the preferred induction regimen in Argentina, based on safety profile. Frontline autologous stem cell transplantation improves quality of responses, especially in countries with limited access to new drugs. 相似文献
10.